Month: November 2022

On December 31, 2009, Muthuppalniappan, Meyyappan; Thomas, Abraham; Kumar, Sukeerthi; Margal, Sanjay; Khairatkar-Joshi, Neelima; Mukhopadhyay, Indranil; Gullapalli, Srinivas published a patent.Reference of 2-Amino-4-(4-iodophenyl)thiazole The title of the patent was Preparation of quinazolinedione derivatives as TRPA1 modulators. And the patent contained the following:

The title compounds I [ring A = (hetero)aryl, heterocyclyl, cycloalkyl; R1, R2 = H, OH, alkyl, etc.; R3, R4 = H, OH, halo, etc.; or R3 and R4 may be joined together to form (un)substituted 3-7 membered (un)saturated cyclic ring which may optionally include one or more heteroatom or group selected from O, S, C(O), S(O)0-2, (un)substituted NH; R5 = H, OH, alkyl, etc.; R6 = H, CN, NO2, etc.; n = 0-5], useful as TRPA (Transient Receptor Potential subfamily A) modulators for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1), were prepared E.g., a multi-step synthesis of II, starting from 2-amino-6-nitrobenzoic acid and urea, was given. Exemplified compounds I were screened for TRPA1 activity. For example, II showed 90.73% inhibition at 10.0 μM using the 45Calcium Uptake Assay. Also provided are processes for preparing compounds I, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1. The experimental process involved the reaction of 2-Amino-4-(4-iodophenyl)thiazole(cas: 31699-14-6).Reference of 2-Amino-4-(4-iodophenyl)thiazole

The Article related to quinazolinedione preparation transient receptor potential channel trpa1 modulator, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Reference of 2-Amino-4-(4-iodophenyl)thiazole

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

Goswami, K. V.; Parajapati, S. N.; Goswami, T. K.; Chaudhari, H. D.; Parmar, Kokila A. published an article in 2019, the title of the article was Spectral and microbial screening of one-pot multicomponent synthesis of fused quinazolinone derivatives.Quality Control of 4-Phenylthiazol-2-amine And the article contains the following content:

Heterocyclic compounds containing 2-chloro-3-formyl pyridine and 2-amino thiazole quinqzolin-6(7H)-one I (R = H, Me, OMe; R1 = H, OMe, OH; R2 = H, Me) are reported to possess significant biol. activity. Synthesis of fused quinazolinone derivatives I have been described. The above synthesized compounds have been evaluated for their antimicrobial activity. Among the series containing some of the compounds showed promising results against standard drugs. The experimental process involved the reaction of 4-Phenylthiazol-2-amine(cas: 2010-06-2).Quality Control of 4-Phenylthiazol-2-amine

The Article related to pyridinyl dihydro thiazoloquinazolinone preparation antibacterial antifungal activity, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Quality Control of 4-Phenylthiazol-2-amine

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On June 7, 2018, Wunderlich, Winfried; Huber, Lukas A.; Leban, Johann Jakob; Pato, Janos; Oerfi, Laszlo; Frigyes, Waczek; Banhegyi, Peter; Sipos, Anna; Szantai-Kis, Csaba published a patent.Category: thiazole The title of the patent was Preparation of 3-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones as cyclin dependent kinase inhibitors for the treatment and prophylaxis of cancer. And the patent contained the following:

The invention relates to preparation of pyrazolopyrimidinones of formulas I and II wherein X1 and X4 each independently H, halo, C1-6 alkoxy; X2 is H or halo; X3 is H, COOH, etc., as cyclin dependent kinase (CDK) inhibitors, pharmaceutical compositions comprising the same and the use thereof in particular in the prophylaxis and treatment of cancer and other proliferative diseases. Furthermore the invention relates to processes for the preparation of said 3-amino-pyrazolo[3,4d]pyrimidin-4-ones and intermediates to be used in the processes of the invention. The experimental process involved the reaction of Methyl 2-(2-aminothiazol-4-yl)acetate(cas: 64987-16-2).Category: thiazole

The Article related to pyrazolopyrimidinone preparation cdk inhibitor proliferative disease cancer treatment prophylaxis, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Category: thiazole

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On July 21, 2011, Kallander, Lara S.; Lawhorn, Brian Griffin; Philip, Joanne; Zhao, Yongdong published a patent.Formula: C6H8N2O2S The title of the patent was 3-[(6-Aminopyrimidin-4-yl)amino]benzenesulfonamide compounds useful as TNNI3K inhibitors, their preparation, and methods of use in the treatment of congestive heart failure. And the patent contained the following:

Title compounds I are disclosed [wherein R1 = C1-4 alkyl; R2 = H, halo; R3 = H, halo, (un)substituted alkyl or alkoxy, aryl, OH, cycloalkyl, alkylthio, amino, (di)(alkyl)amino; R4 = H, halo, (un)substituted alkyl or alkoxy, OH, (halo)alkylthio, alkylsulfonyl, (un)substituted amino; R5 = H; or R4 and R5 form a 5 or 6 membered ring, optionally substituted or containing one or two addnl. N/O/S atoms; R6 = alky(en/yn)yl, cycloalkyl, (un)substituted (hetero)aryl; and salts]. I are inhibitors of cardiac troponin I-interacting kinase (TNNI3K), also known as CARK (for cardiac ankyrin repeat kinase), a protein kinase that exhibits highly selective expression for cardiac tissues and which has been shown to interact with components of the sarcomere, including troponin I. Approx. 380 compounds I are claimed as the free base, and were prepared as salts and/or free bases. Numerous intermediates were also prepared For instance, the intermediate 3-[(6-chloro-4-pyrimidinyl)amino]-N-methylbenznesulfonamide and 3-biphenylamine were microwaved together in isopropanol in the presence of concentrated HCl at 150° for 20 min to give invention compound II, isolated as the trifluoroacetate. In bioassays using human TNNI3K, I exhibited pXC50 ≥ approx. 6.0. For instance, two compounds I inhibited hTNNI3K with a mean pXC50 of approx. 7.0. The experimental process involved the reaction of Methyl 2-(2-aminothiazol-4-yl)acetate(cas: 64987-16-2).Formula: C6H8N2O2S

The Article related to pyrimidinylamino benzenesulfonamide preparation tnni3k inhibitor treatment congestive heart failure, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Formula: C6H8N2O2S

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On November 13, 2008, Yamashita, Haruhisa; Odai, Osamu; Harada, Hiroshi; Iwata, Mitsutaka published a patent.Formula: C6H8N2O2S The title of the patent was Preparation of fused heterocyclic derivatives as glucokinase (GK) activators. And the patent contained the following:

Title compounds I [A = -N(R3)(CH2)m-, -N(R3)CO(CH2)m- or -N(R3)SO2(CH2)m-; m = 0-2; X1, X2 = -CO-, -CS- or -C(R4)(R5)-; X3 = -C(R4)(R5)-; R1 = H, (un)substituted alkyl, (un)substituted cycloalkyl, etc.; R2 = H, (un)substituted alkyl, (un)substituted alkenyl, etc.; R3 = H, (un)substituted alkyl or (un)substituted cycloalkyl; R4, R5 = H, halo or (un)substituted alkyl; n = 1 or 2] or their pharmaceutically acceptable salts were prepared For example, Pd2(dba)3 catalyzed reaction of compound II [R = Cl], e.g., prepared from Et 4-oxopiperidine-3-carboxylate hydrochloride in 3 steps, with 2-aminothiazole afforded compound II [R = thiazol-2-ylamino], which showed 328% GK activation. Compounds I are claimed useful for the treatment of diabetes. The experimental process involved the reaction of Methyl 2-(2-aminothiazol-4-yl)acetate(cas: 64987-16-2).Formula: C6H8N2O2S

The Article related to fused heterocycle preparation glucokinase gk activator, diabetes treatment fused heterocycle preparation gk activation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Formula: C6H8N2O2S

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On June 30, 2021, Abdel-Aziz, Salah A.; Taher, Ehab S.; Lan, Ping; Asaad, Gihan F.; Gomaa, Hesham A. M.; El-Koussi, Nawal A.; Youssif, Bahaa G. M. published an article.Safety of 4-Phenylthiazol-2-amine The title of the article was Design, synthesis, and biological evaluation of new pyrimidine-5-carbonitrile derivatives bearing 1,3-thiazole moiety as novel anti-inflammatory EGFR inhibitors with cardiac safety profile. And the article contained the following:

A new series of pyrimidine-5-carbonitrile derivatives carrying the 1,3-thiazole moiety has been designed and synthesized as novel anti-inflammatory EGFR inhibitors with cardiac and gastric safety profiles and have been assessed for their inhibitory activity against COX-1/COX-2. Compounds 8h, 8n, and 8p (I – III, resp.) were found to be potent and selective COX-2 inhibitors (IC50 = 1.03-1.71μM) relative to celecoxib (IC50 = 0.88μM). The most potent COX-2 inhibitors have been further investigated for their in-vivo anti-inflammatory effect. Compounds 8h, 8n, and 8p showed anti-inflammatory activity up to 90%, 94% and 86% of meloxicam after 4 h interval. 8h, 8n, and 8p showed higher gastric safety profiles than meloxicam. A substantial reduction in serum concentrations of PGE2, TNF-α, IL-6, iNO and MDA and a significant induction of TAC was also observed In vivo experiments on heart rate and blood pressure established the cardiovascular safety profile of 8h, 8n, and 8p. Anti-proliferative and wild-type EGFR inhibitory assays displayed similar results to selective COX-2 inhibition where compounds 8h, 8n, and 8p had a superior inhibition than other tested ones. Mol. docking study demonstrated that these compounds revealed similar orientation and binding interactions as selective COX-2 inhibitors with a higher liability to enter the side pocket selectively. Also, they interacted with EGFR tyrosine kinase main amino acids similar to erlotinib with a strong binding energy score. The experimental process involved the reaction of 4-Phenylthiazol-2-amine(cas: 2010-06-2).Safety of 4-Phenylthiazol-2-amine

The Article related to pyrimidinecarbonitrile thiazole antiinflammatory egfr inhibitor cardiac safety, cox, egfr, il-6, lox, pge(2), pyrimidine, thiazole, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Safety of 4-Phenylthiazol-2-amine

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On September 30, 2021, Mohamed Teleb, Mohamed A.; Mekky, Ahmed E. M.; Sanad, Sherif M. H. published an article.Formula: C9H8N2S The title of the article was 3-Aminothieno [2,3-b]pyridine-2-carboxylate: Effective precursor for microwave-assisted three components synthesis of new pyrido[3′,2′:4,5]thieno[3,2-d]pyrimidin-4( 3H )-one hybrids. And the article contained the following:

In this study, Et 3-aminothieno[2,3-b]pyridine-2-carboxylate was taken as a versatile precursor for the one-pot three-component synthesis of related fused pyrimidine hybrids. The tandem protocol involved the reaction of 3-aminothieno[2,3-b]pyridine, dimethylformamide-dimethylacetal, and amines. The reaction afforded a new series of the target pyrimidine hybrids, linked to different arene units I (X = H, NO2, COOEt, etc.), in good to excellent yields. The prior reaction was evaluated in different solvents under traditional heating or microwave irradiation Moreover, the influence of reaction temperature was also examined The optimal conditions were obtained under microwave irradiation in dioxane at 110°C for 40 to 60 min. Addnl., by repeating the previous tandem reaction using the appropriate amines at reaction times of 20 to 60 min, a new series of pyrimidine hybrids linked to alkyl, arylthiazole, and benzo[d]thiazole units has been prepared in good to excellent yields. Furthermore, the utility of bis(amines) was examined to conduct the synthesis of new bis(pyrimidine) hybrids linked to aliphatic cores, in excellent yields, using the same protocol at 30 min reaction time. The experimental process involved the reaction of 4-Phenylthiazol-2-amine(cas: 2010-06-2).Formula: C9H8N2S

The Article related to pyridothienopyrimidinone hybrid preparation microwave irradiation, aminothienopyridine dmf dimethylacetal amine three component reaction, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Formula: C9H8N2S

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On October 18, 2012, Holcomb, Ryan C.; Sebahar, Paul R.; Suzuki, Kazuyuki; McLeod, Donald A.; Dastrup, David M.; Hoarau, Christophe; Halter, Robert J.; Bursavich, Matthew Gregory; Shenderovich, Mark D.; Richards, Burt; Bartel, Paul L. published a patent.Product Details of 64987-16-2 The title of the patent was Preparation of substituted pyrimidinylbenzonitriles as IKK-related kinase ε and TANK-binding kinase 1 inhibitors. And the patent contained the following:

The invention relates to compounds I [R1 = (un)substituted heteroaryl, heterocyclyl, heteroarylalkylene, etc.; R2 = alkyl, cycloalkyl, aryl, etc.; R3-R7 = alkyl, cycloalkyl, aryl, etc.; with the provisos], pharmaceutical compositions and medicaments comprising such compounds, and the use of these compounds, compositions, and medicaments in methods of treating diseases and disorders. Two-hundred-fifty-three compounds I were prepared E.g., a multi-step synthesis of II, starting from 5-bromo-2-hydroxybenzonitrile and tetrahydro-2H-pyran-4-ol, was described. Exemplified compounds I were tested in in vitro IKKε and TBK1 kinase assays (data given). The experimental process involved the reaction of Methyl 2-(2-aminothiazol-4-yl)acetate(cas: 64987-16-2).Product Details of 64987-16-2

The Article related to pyrimidinylbenzonitrile preparation ikk epsilon tbk1 kinase inhibitor, pyrimidinyl benzonitrile preparation tank binding kinase 1 inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Product Details of 64987-16-2

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

Mohanta, Prajna Parimita; Pati, Hari Narayan; Behera, Ajaya Kumar published an article in 2020, the title of the article was The construction of fluorophoric thiazolo-[2,3-b]quinazolinone derivatives: a multicomponent domino synthetic approach.Reference of 4-Phenylthiazol-2-amine And the article contains the following content:

Acid-mediated one-pot domino reactions of substituted 2-aminothiazoles, substituted benzaldehydes and cyclic diketones have been developed for the synthesis of novel and architecturally unique thiazolo[2,3-b]quinazolinone derivatives I (Ar = C6H5, 4-CH3OC6H4, 4-BrC6H4, etc.; Ar1 = C6H5, 4-H3CC6H4, 4-ClC6H4, etc.; R1 = R2 = H, CH3) under microwave irradiation In this protocol, a series of thiazolo[2,3-b]quinazolinone derivatives have been synthesized and the excellent fluorescence behaviors of some of the mols. have been reported based on the incorporation of different electron-donating and electron-withdrawing substituents on the aryl moieties of the target mols. The experimental process involved the reaction of 4-Phenylthiazol-2-amine(cas: 2010-06-2).Reference of 4-Phenylthiazol-2-amine

The Article related to thiazoloquinazolinone preparation microwave irradiation fluorescence, aminothiazole benzaldehyde cyclic diketone domino multicomponent reaction, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Reference of 4-Phenylthiazol-2-amine

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On November 7, 2019, Tarby, Christine M.; Norris, Derek J.; Lo, Julian C.; Ahuja, Vijay T.; Seitz, Steven P.; Gavai, Ashvinikumar V.; Tokarski, John S.; Rajasagi, Mohini; Wichroski, Michael; Broekema, Matthias published a patent.HPLC of Formula: 64987-16-2 The title of the patent was Preparation of uracil derivatives as Mer-Axl inhibitors. And the patent contained the following:

The invention relates generally to compounds I [Ar1 = aryl or heteroaryl containing 1-4 heteroatoms selected from N, O or S; Ar2 = heteroaryl containing 1-4 heteroatoms selected from N, O or S; Q1 = NHCO, CONH, NHSO2, etc.; Q2 = O or NH; R1 and R2 = (independently) H, (un)substituted alkyl, (CH2)r(cycloalkyl), etc.; R3 and R4 = (independently) H, halo, CF3, etc.; X and Y = (independently) H, halo, alkyl, etc.; r = 0-2] or pharmaceutically acceptable salts, tautomers or stereoisomers thereof, that are Mer-Axl inhibitors, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention. Over one-hundred-forty compounds I were prepared E.g., a multi-step synthesis of II, starting from di-Et 2-(aminomethylene)malonate and 1-fluoro-4-isocyanatobenzene, was described. The inhibitory activity of compounds I was tested in the MERTK, AXL, and TYRO3 activity assays (data given for representative compounds I). The experimental process involved the reaction of Methyl 2-(2-aminothiazol-4-yl)acetate(cas: 64987-16-2).HPLC of Formula: 64987-16-2

The Article related to uracil derivative preparation mer axl tyro3 kinase inhibitor antitumor, proliferative disorder dysregulated apoptosis treatment uracil derivative preparation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.HPLC of Formula: 64987-16-2

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica